Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells

Total Page:16

File Type:pdf, Size:1020Kb

Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses Reza Nadafi, Catarina Gago de Graça, Eelco Keuning, Jasper Koning, Sander de Kivit, Tanja Konijn, Sandrine Henri, Jannie Borst, Rogier Reijmers, Lisa G.M. van Baarsen, et al. To cite this version: Reza Nadafi, Catarina Gago de Graça, Eelco Keuning, Jasper Koning, Sander de Kivit, etal.. Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autore- active T and B Cell Responses. Cell Reports, Elsevier Inc, 2020, 30 (12), pp.4110-4123.e4. 10.1016/j.celrep.2020.03.007. hal-02982506 HAL Id: hal-02982506 https://hal.archives-ouvertes.fr/hal-02982506 Submitted on 21 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Article Lymph Node Stromal Cells Generate Antigen- Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses Graphical Abstract Authors Reza Nadafi, Catarina Gago de Grac¸a, Eelco D. Keuning, ..., Rogier M. Reijmers, Lisa G.M. van Baarsen, Reina E. Mebius Correspondence [email protected] In Brief Lymph node stromal cells influence adaptive immune cells in various ways. Nadafi et al. show that by presenting self- antigens on MHC class II, lymph node stromal cells promote the differentiation of CD4+ T cells into regulatory T cells, which are able to prevent the generation of follicular T helper cells and germinal center B cells directed against the same self-antigen. Highlights d Lymph node stromal cells convert naive CD4+ T cells into TREG cells d Conversion of TREG cells by lymph node stromal cells is IL-2 dependent d Autoreactive TFH cells and B cells are controlled by lymph node stromal cells Nadafi et al., 2020, Cell Reports 30, 4110–4123 March 24, 2020 ª 2020 The Author(s). https://doi.org/10.1016/j.celrep.2020.03.007 Cell Reports Article Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses Reza Nadafi,1,2 Catarina Gago de Grac¸a,1 Eelco D. Keuning,1 Jasper J. Koning,1 Sander de Kivit,2,3 Tanja Konijn,1 Sandrine Henri,4 Jannie Borst,2,3 Rogier M. Reijmers,1,7 Lisa G.M. van Baarsen,5,6 and Reina E. Mebius1,8,* 1Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands 2Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands 3Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands 4Centre d’Immunologie de Marseille-Luminy, Aix Marseille Universite, INSERM, CNRS, 13288 Marseille, France 5Department of Rheumatology and Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC and University of Amsterdam, Amsterdam, the Netherlands 6Amsterdam Rheumatology and Immunology Center (ARC), Academic Medical Center, Amsterdam, the Netherlands 7Present address: LUMICKS, Pilotenstraat 41, Amsterdam, the Netherlands 8Lead Contact *Correspondence: [email protected] https://doi.org/10.1016/j.celrep.2020.03.007 SUMMARY the development of a broad range of autoimmune diseases such as juvenile dermatomyositis (Morita et al., 2011), Sjogren’s Within lymph nodes (LNs), T follicular helper (TFH) syndrome (Simpson et al., 2010; Szabo et al., 2013), systemic cells help B cells to produce antibodies, which can lupus erythematous (He et al., 2013; Simpson et al., 2010), and either be protective or autoreactive. Here, we rheumatoid arthritis (Arroyo-Villa et al., 2014; Ma et al., 2012; demonstrate that murine LN stromal cells (LNSCs) Rao et al., 2017; Wang et al., 2013; Zhang et al., 2015). TFH cells differentiate within the T cell area of lymph nodes (LNs) and are suppress the formation of autoreactive TFH cells in an antigen-specific manner, thereby significantly identified by the expression of Cxcr5, PD-1, and Bcl6 (Crotty, 2014). Bcl6 is an essential transcription factor for their develop- reducing germinal center B cell responses directed ment, while expression of chemokine receptor Cxcr5 guides TFH against the same self-antigen. Mechanistically, cell migration to B cell follicles, where they contribute to the LNSCs express and present self-antigens in major maturation and differentiation of B cells (Crotty, 2014). histocompatibility complex (MHC) class II, leading Regulatory pathways need to be in place to control the forma- + to the conversion of naive CD4 T cells into T regula- tion and development of autoreactive TFH cells. Among diverse tory (TREG) cells in an interleukin-2 (IL-2)-dependent regulatory mechanisms, it is particularly important to mention manner. Upon blockade of TREG cells, using neutral- the fundamental role of T regulatory (TREG) cells in preventing izing IL-2 antibodies, autoreactive TFH cells are autoreactive T cell formation in the thymus and periphery (Jose- allowed to develop. We conclude that the continuous fowicz et al., 2012). Generation of TREG cells in the thymus is the presentation of self-antigens by LNSCs is critical to result of the recognition of self-antigens by T cells bearing a high- generate antigen-specific T cells, thereby repres- affinity T cell receptor (TCR) (Jordan et al., 2001). Expression of REG the vast majority of self-antigens in the thymus is restricted to sing the formation of T cells and germinal center B FH a unique non-hematopoietic stromal cell population known as cell responses. Our findings uncover the ability of medullary thymic epithelial cells (mTECs), which are able to steer LNSCs to suppress the early activation of autoreac- the differentiation of CD4+ T cells with high-affinity TCRs into + tive immune cells and maintain peripheral tolerance. FoxP3 TREG cells (Anderson et al., 2002; Aschenbrenner et al., 2007; Derbinski et al., 2001; Hinterberger et al., 2010). The INTRODUCTION expression and presentation of self-antigens, however, is not limited to mTECs in the thymus, as several LN stromal cell Autoimmunity emerges when immune tolerance against self-an- (LNSC) subsets— including fibroblastic reticular cells (FRCs), tigens is lost. As a result, the recognition of self-antigens by cells lymphatic endothelial cells (LECs), blood endothelial cells of the adaptive immune system leads to the formation and devel- (BECs), and double-negative (DN) cells—also display unique opment of autoreactive B cells in germinal centers (GCs) and expression patterns of self-antigens (Cohen et al., 2010; Fletcher autoantibody production (Yanaba et al., 2008). T follicular helper et al., 2010; Nichols et al., 2007). The effect of self-antigen pre- (TFH) cells are speculated to be the central players in the sentation by LNSCs on autoreactive T cells has been shown in pathogenesis of autoimmune diseases by steering a selective various studies (Cohen et al., 2010; Dubrot et al., 2014; Fletcher expansion of high-affinity autoreactive B cells in GCs (Craft, et al., 2010; Lee et al., 2007; Magnusson et al., 2008; Nichols 2012). Accordingly, alterations in TFH cells are associated with et al., 2007; Rouhani et al., 2015), suggesting that the process 4110 Cell Reports 30, 4110–4123, March 24, 2020 ª 2020 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Figure 1. Antigen-Specific TREG Cell Conversion Occurs in the Lymph Nodes 6 (A) In vivo experimental design to study TREG cell conversion in LNs. WT C57L/6J and K14-mOva mice were intravenously injected with 5–8 3 10 CFSE-labeled CD4+ OT-II.Rag2À/À T cells. 1 and 3 days after CD4+ T cell transfer, mice were sacrificed, and LNs were isolated for analysis of transferred CD4+ OT-II.Rag2À/À T cells by flow cytometry (B and C) and immunofluorescence (D and E). (B) Representative contour plots of live CFSE-labeled CD4+CD3+ OT-II.Rag2À/À T cells in peripheral LNs, in which the numbers in the plots display the frequency + + of CD25 FoxP3 TREG cells. (legend continued on next page) Cell Reports 30, 4110–4123, March 24, 2020 4111 of peripheral tolerance is necessary to further complete TREG cell the contribution of LNSCs in TREG cell conversion in vivo, naive generation in the thymus. carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4+ Recently, we have demonstrated that LNSCs constrain T cells from OT-II.Rag2À/À, which lack endogenous thymic + + immune reactivity via presentation of self-antigens in major his- CD25 FoxP3 TREG cells (Figure S1B), were intravenously in- tocompatibility complex (MHC) class II, which results in the jected into wild-type (WT) C57BL/6J and K14-mOva mice. LNs + selective maintenance of antigen-specific TREG cells (Baptista were isolated 1 and 3 days after the CFSE-labeled CD4 T cell et al., 2014). The expression of MHC class II by LNSCs and not transfer (Figure 1A). Analysis of peripheral (axillary, brachial, dendritic cells (DCs) was shown to be critical to preventing the inguinal, and popliteal) LNs at day 3 showed that Ova-specific activation of both CD4+ and CD8+ cells (Baptista et al., 2014; TCR-transgenic CD4+CD3+ OT-II.Rag2À/À T cells converted + + Dubrot et al., 2018). Nevertheless, the question of whether into CD25 FoxP3 TREG cells solely in K14-mOva LNs, wherein self-antigen presentation by LNSCs may in fact induce anti- Ova is exclusively expressed as a self-antigen by LNSCs.
Recommended publications
  • CD27 CD70 Is Downregulated by Interaction With
    CD70 Is Downregulated by Interaction with CD27 Mirela Kuka, Ivana Munitic, Maria Letizia Giardino Torchia and Jonathan D. Ashwell This information is current as of September 25, 2021. J Immunol 2013; 191:2282-2289; Prepublished online 2 August 2013; doi: 10.4049/jimmunol.1300868 http://www.jimmunol.org/content/191/5/2282 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/06/jimmunol.130086 Material 8.DC1 References This article cites 35 articles, 19 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/191/5/2282.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 25, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD70 Is Downregulated by Interaction with CD27 Mirela Kuka,1,2 Ivana Munitic,1,3 Maria Letizia Giardino Torchia, and Jonathan D. Ashwell Engagement of the receptor CD27 by CD70 affects the magnitude and quality of T cell responses in a variety of infection models, and exaggerated signaling via this pathway results in enhanced immune responses and autoimmunity.
    [Show full text]
  • 7432.Full.Pdf
    CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation This information is current as Yanling Xiao, Jenny Hendriks, Petra Langerak, Heinz Jacobs of September 29, 2021. and Jannie Borst J Immunol 2004; 172:7432-7441; ; doi: 10.4049/jimmunol.172.12.7432 http://www.jimmunol.org/content/172/12/7432 Downloaded from References This article cites 43 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/172/12/7432.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation1 Yanling Xiao, Jenny Hendriks, Petra Langerak, Heinz Jacobs, and Jannie Borst2 Studies on human B cells have featured CD27 as a marker and mediator of the B cell response.
    [Show full text]
  • Uva-DARE (Digital Academic Repository)
    UvA-DARE (Digital Academic Repository) Contributions of CD27 and relatives to the specific immune response Hendriks, J.A. Publication date 2004 Link to publication Citation for published version (APA): Hendriks, J. A. (2004). Contributions of CD27 and relatives to the specific immune response. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:24 Sep 2021 Chapter 5 CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. Yanling Xiao, Jenny Hendriks, Petra Langerak, Heinz Jacobs and Jannie Borst The Journal of Immunology 2004 172: 7432-7441 67 68 CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation1 Yanling Xiao, Jenny Hendriks, Petra Langerak, Heinz Jacobs, and Jannie Borst2 Studies on human B cells have featured CD27 as a marker and mediator of the B cell response.
    [Show full text]
  • Uva-DARE (Digital Academic Repository)
    UvA-DARE (Digital Academic Repository) Molecular basis of CD4+ T cell help for the cytotoxic T cell response Ahrends, T.J. Publication date 2018 Document Version Other version License Other Link to publication Citation for published version (APA): Ahrends, T. J. (2018). Molecular basis of CD4+ T cell help for the cytotoxic T cell response. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:08 Oct 2021 CURRICULUM VITAE LIST OF PUBLICATIONS & WORD OF THANKS ADDENDUM CURRICULUM VITAE Tomasz Ahrends was born on December 30th, 1988 in Gdańsk (Poland). In 2010 he obtained Bachelor’s degree in Biotechnology at the Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk. Subsequently, he continued his education with a Master’s degree in Biotechnology, which he fnished in 2012.
    [Show full text]
  • PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/27226 Please be advised that this information was generated on 2021-09-26 and may be subject to change. 1142 G. D. Keizer, J. Borst, C. G. Figdor et al Eur. J. Immunol. 1985.15: 1142-1147 Gerrit D. Keizer0, Jannie Borst°, Biochemical and functional characteristics of the Carl G. Figdor0 , Hergen Spits0 , Frank MiedemaA, Cox TerhorstD human leukocyte membrane antigen family LFA-1, and Jan E. De Vries0 Mo-1 and pl50,95* Division of Immunology, The Netherlands Cancer Institute (Antoni The human leukocyte function-associated (LFA-1) antigen, the monocyte differentia­ van Leeuwenhoek Huis)0 , Amsterdam, tion antigen Mo-1 which is characterized as the C3bi receptor and the glycoprotein Central Laboratory of the Netherlands p i50,95 are characterized biochemically. Immunoprecipitations carried out with 6 Red Cross Blood Transfusion ServiceA, different monoclonal antibodies (mAb) against LFA-1 indicated that four mAb (SPV- Amsterdam and Dana-Farber Cancer Ll, SPV-L5, SPV-L7 and SPV-L11) were directed against the a chain, whereas mAb Institute0, Boston CLB54 and MHM-23 were found to react with the common |3 chain of LFA-1, Mo-1 and p 150,95. LFA-1 and Mo-1 expressed on KG-1 cells or lymphocytes, monocytes and granulocytes from one donor were homogeneous. Interestingly the a chain of pl50,95 showed heterogeneity. The molecular weight of the a chain expressed on monocytes was consistently higher than that of the a chain on granulocytes.
    [Show full text]
  • Radio-Immunotherapy in Cancer
    Radio-immunotherapy in cancer Inge Verbrugge The Netherlands Cancer Institute Radiotherapy • One of three /four main treatment modalities • Used in ~50% of cancer patients • Administered locally: minimizes normal tissue damage Effects of radiotherapy on tumor cell clonogenicity DNA damage 1. (Irreversible) cell cycle arrest senescence 2. Death due to mitotic catastrophe 3. Apoptotic cell death Radiotherapy alone may not be curative RADIOTHERAPY Curing metastasized cancer with systemic therapy • Immunotherapy - Eliciting systemic anti-tumor cytotoxic T cell (CTL) responses (CTL) MHC I Radiotherapy: Clinical systemic (=‘abscopal’) responses Pre-radiotherapy Post-radiotherapy ‘Abscopal Effect’ Ohba K et al., Gut 1998;43:575-577 Radiotherapy may support local and systemic tumor immunity Radiotherapy may support local and systemic tumor immunity Co-stimulation ‘abscopal effect’ Established tumors evade immune responses Bottlenecks 1. Lack of recognizable ‘tumor’ antigens 2. Lack of ‘danger signals’ 3. Lack of T cell infiltration into tumor 4. Inhibition CTL activity by tumor / tumor micro-environment Antibodies modulating T cell responses Ipilimumab Pembrolizumab Nivolumab Mellman I et al., Nature 2011;480:480-489 Antibodies modulating T cell responses Ipilimumab Pembrolizumab Nivolumab Mellman I et al., Nature 2011;480:480-489 Antibody-based immunotherapy: local and systemic effects Co-inhibitory receptor Co-stimulatory receptor Radio-immunotherapy: Combining radiotherapy with immunotherapy Blocking coinhibition α-PD-1, α-CD137 Costimulation Radio-immunotherapy promise: Achieving SYSTEMIC synergism by combining LOCAL radiotherapy with immune-modulation Radio-immunotherapy: opportunities Blocking coinhibition α-PD-1, α-CD137 Costimulation 1. Inducing curative local combined responses 2. Achieving systemic combined effect by promoting relevant immune responses Radio-immunotherapy induces local tumor control α-PD-1 α-PD-1, α-CD137 α-CD137 Achieving systemic combined effects by radio-immunotherapy Blocking coinhibition α-PD-1, α-CD137 Costimulation 2.
    [Show full text]
  • Effector T Cell Pool + CD8 Costimulation to Promote
    CD8+ T Cells Produce the Chemokine CXCL10 in Response to CD27/CD70 Costimulation To Promote Generation of the CD8 + Effector T Cell Pool This information is current as of October 2, 2021. Victor Peperzak, Elise A. M. Veraar, Yanling Xiao, Nikolina Babala, Klaske Thiadens, Marieke Brugmans and Jannie Borst J Immunol 2013; 191:3025-3036; Prepublished online 12 August 2013; Downloaded from doi: 10.4049/jimmunol.1202222 http://www.jimmunol.org/content/191/6/3025 Supplementary http://www.jimmunol.org/content/suppl/2013/08/12/jimmunol.120222 http://www.jimmunol.org/ Material 2.DC1 References This article cites 56 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/191/6/3025.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD8+ T Cells Produce the Chemokine CXCL10 in Response to CD27/CD70 Costimulation To Promote Generation of the CD8+ Effector T Cell Pool Victor Peperzak,1 Elise A.
    [Show full text]
  • Pulling the Strings on Anti-Cancer Immunity Issue Date: 2017-02-07
    Cover Page The handle http://hdl.handle.net/1887/45885 holds various files of this Leiden University dissertation. Author: Kersten, K. Title: Pulling the strings on anti-cancer immunity Issue Date: 2017-02-07 Pulling the strings on anti-cancer immunity Kelly Kersten About the cover: Based on the research described in this thesis and inspired by the song ‘Master of Puppets’ by Metallica, I envision cancer as a puppet-master restraining the protective function of the immune system. Part of my PhD work has focused on how tumor cells manipulate the function of immune cells to favor their spread throughout the body. In other words, cancer is pulling the strings on anti-cancer immunity to prevent destruction by the immune system. With the recent advances of combinatorial anti-cancer therapies (including immunomodulatory drugs) we can gain back control over the strings on anti-cancer immunity. Cover design: Kelly Kersten & Tomasz Ahrends Artwork: Tomasz Ahrends Lay-out: Jasper Koning ([email protected]) Printing: Gildeprint, Enschede ISBN: 978-94-6233-496-0 The printing of the thesis was financially supported by the NKI-AVL. ©2016 by Kelly Kersten. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission of the author and the publisher holding the copyright of the articles. The research described in this thesis was performed at the Divisions of Molecular Biology and Immunology of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, The Netherlands, and was supported by the Dutch Cancer Society (KWF2011-5004) and the European Research Council (InflaMet 615300).
    [Show full text]
  • Tetanus Toxoid Endo-F
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/27226 Please be advised that this information was generated on 2021-09-25 and may be subject to change. 1142 G. D. Keizer, J. Borst, C. G. Figdor et al Eur. J. Immunol. 1985.15: 1142-1147 Gerrit D. Keizer0, Jannie Borst°, Biochemical and functional characteristics of the Carl G. Figdor0 , Hergen Spits0 , Frank MiedemaA, Cox TerhorstD human leukocyte membrane antigen family LFA-1, and Jan E. De Vries0 Mo-1 and pl50,95* Division of Immunology, The Netherlands Cancer Institute (Antoni The human leukocyte function-associated (LFA-1) antigen, the monocyte differentia­ van Leeuwenhoek Huis)0 , Amsterdam, tion antigen Mo-1 which is characterized as the C3bi receptor and the glycoprotein Central Laboratory of the Netherlands p i50,95 are characterized biochemically. Immunoprecipitations carried out with 6 Red Cross Blood Transfusion ServiceA, different monoclonal antibodies (mAb) against LFA-1 indicated that four mAb (SPV- Amsterdam and Dana-Farber Cancer Ll, SPV-L5, SPV-L7 and SPV-L11) were directed against the a chain, whereas mAb Institute0, Boston CLB54 and MHM-23 were found to react with the common |3 chain of LFA-1, Mo-1 and p 150,95. LFA-1 and Mo-1 expressed on KG-1 cells or lymphocytes, monocytes and granulocytes from one donor were homogeneous. Interestingly the a chain of pl50,95 showed heterogeneity. The molecular weight of the a chain expressed on monocytes was consistently higher than that of the a chain on granulocytes.
    [Show full text]
  • Differentiation Antigens of Human Hemopoietic Cells: Patterns of Reactivity of Two Monoclonal Antibodies1
    [CANCER RESEARCH 43, 4812-4815, October 1983] Differentiation Antigens of Human Hemopoietic Cells: Patterns of Reactivity of Two Monoclonal Antibodies1 Silvana Passano,2 Lisabianca Bùttero, Jeffrey Faust, Massimo Trucco, Antonio Palumbo, Luigi Pegoraro, Beverly Lange, Colette Brezin, Jannie Borst, Cox Terhorst, and Giovanni Rovera The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104 [S. P., L. B., J. F., M. T., A. P., G. R.]; The Institute of Internal Medicine, University of Turin, Italy [L. P.]; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [B. L); and The Dana-Farber Cancer Institute, Boston, Massachusetts 02115 [C. B., J. B., C. T.] ABSTRACT terized the surface antigens recognized by 2 monoclonal anti bodies generated by immunizing mice with AML cells. These Two mouse anti-human monoclonal antibodies (S3.13 and antibodies are reactive with a large number of leukemic cell lines S5.7) raised against cells of acute myelogenous leukemia were and have a complex distribution on hemopoietic cells. found to react with antigens expressed on the surface of subsets of monocytes and lymphocytes. MATERIALS AND METHODS S3.13 precipitates a peptide of M, 29,000, and S5.7 precipi tates a peptide of M, 20,000 present on the surface of all the cell Hemopoietic Tissues. Normal peripheral blood and marrow for these types tested. These two surface antigens were distributed on investigations were obtained from healthy volunteer donors and ap proved by the Committee for the Protection of Human Subjects of The discrete subpopulations of normal hemopoietic cells. The anti Wistar Institute. bodies reacted with all (S5.7) or a subpopulation (S3.13) of Mononuclear cells were separated by FicolhHypaque (D = 1.078) peripheral blood T-lymphocytes, and with a subset of monocytes.
    [Show full text]
  • GPA33: a Marker to Identify Stable Human Regulatory T Cells
    The Journal of Immunology GPA33: A Marker to Identify Stable Human Regulatory T Cells Rianne Opstelten,* Sander de Kivit,†,1 Manon C. Slot,* Maartje van den Biggelaar,‡ Dorota Iwaszkiewicz-Grzes,x Mateusz Gliwin´ski,x Andrew M. Scott,{ Bianca Blom,‖ Piotr Trzonkowski,x Jannie Borst,†,1 Eloy Cuadrado,* and Derk Amsen* FOXP3-expressing regulatory T (Treg) cells safeguard immunological tolerance. Treg cells can be generated during thymic development (called thymic Treg [tTreg] cells) or derived from mature conventional CD4+ T cells that underwent TGF-b– mediated conversion in the periphery (called peripheral Treg [pTreg] cells). Murine studies have shown that tTreg cells exhibit strong lineage fidelity, whereas pTreg cells can revert into conventional CD4+ T cells. Their stronger lineage commitment makes tTreg cells the safest cells to use in adoptive cell therapy, increasingly used to treat autoimmune and inflammatory disorders. Markers to distinguish human tTreg cells from pTreg cells have, however, not been found. Based on combined proteomic and transcriptomic approaches, we report that the Ig superfamily protein GPA33 is expressed on a subset of human Treg cells. GPA33 is acquired late during tTreg cell development but is not expressed on TGF-b–induced Treg cells. GPA33 identifies Treg cells in human blood that lack the ability to produce effector cytokines (IL-2, IFN-g, IL-17), regardless of differentiation stage. GPA33high Treg cells universally express the transcription factor Helios that preferentially marks tTreg cells and can robustly and stably be expanded in vitro even without rapamycin. Expanded GPA33high Treg cells are suppressive, unable to produce proinflammatory cytokines, and exhibit the epigenetic modifications of the FOXP3 gene enhancer CNS2, necessary for indelible expression of this critical transcription factor.
    [Show full text]
  • CD70 As an Actionable Immunotherapeutic Target in Recurrent Glioblastoma
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.02.446670; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma 1* 2* 1 2 1 2 Seyfrid M , Maich W , Shaikh MV ,Tatari N , Upreti D , Piyasena D , Subapanditha M1, Savage N2, McKenna D1, Kuhlmann L 3, Khoo A3, Salim SK2, Bassey-Archibong B1, Gwynne W1, Chokshi C 2, Brown K4, Murtaza N2, Bakhshinyan D2, Vora P1, Venugopal C1, Moffat J4, Singh SK1,2. *These authors made equal contributions to this paper Departments of 1Surgery, 2Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada 3Princess Margaret’s Hospital, Toronto, Ontario, M5S 3E1, Canada 4Donnelly Centre, Department of Molecular Genetics, University of Toronto, Ontario, Canada RUNNING TITLE CD70 as an immunotherapeutic for recurrent GBM KEYWORDS: Glioblastoma, CD70, Immunotherapy, CAR-T CONFLICTS OF INTEREST: This work was partly funded by Longbow Therapeutics (company no longer in existence) 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.06.02.446670; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]